ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lakshman, R
Right arrow Articles by Finn, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lakshman, R
Right arrow Articles by Finn, A
Topic Collections
Right arrowRelevant Article
Arch Dis Child 2001;85:391-397 ( November )

Article

Safety of a new conjugate meningococcal C vaccine in infants R Lakshmana, I Jonesb, D Walkerb, K McMurtriea, L Shawa, G Racea, S Chooa, L Danzigc, P Osterc, A Finna

a Sheffield Institute for Vaccine Studies, Sheffield Children's Hospital, Sheffield S10 2TH, UK, b Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7LN, UK, c Chiron SpA, via Fiorentina 1, 53100, Siena, Italy

Correspondence to: Dr Lakshman R.Lakshman{at}sheffield.ac.uk

Accepted 11 July 2001

BACKGROUND---Group C conjugate meningococcal vaccines (Men C) were introduced into the UK primary immunisation schedule in November 1999. There has been extensive professional and public interest in their efficacy and safety.
AIM---To determine the occurrence of at least one uncommon adverse event in infants related to the administration of the Chiron Men C vaccine.
METHODS---A total of 2796 infants aged approximately 2 months were recruited into the study from areas in and around Sheffield and from Scotland. They were vaccinated with the Chiron Men C vaccine at 2, 3, and 4 months along with routine immunisations. Data on adverse events occurring one month after each dose were collected actively and prospectively and reviewed for possible relation to the vaccine.
RESULTS---There were no deaths. There were no serious adverse events considered definitely or probably caused by the vaccine. Four infants developed serious adverse events (hypotonia, screaming syndrome, maculopapular rash, and agitation, respectively) that were considered possibly related to the vaccine. All recovered completely. Adverse events were seen in 1804 children but were considered possibly related to the vaccine in only 49 (1.8%). On subsequent immunisation there were no recurrences of adverse events considered to be possibly related to the vaccine.


Keywords: vaccine; meningococcal; Men C; meningitis; immunisation; adverse reaction


© 2001 by Archives of Disease in Childhood

Relevant Article


Arch. Dis. Child. 2001 85: 0. [Extract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health